Aditx Therapeutics Inc. is a life sciences company. It engages in developing biotechnologies specifically focused on health of the immune system through immune monitoring and reprogramming. Aditx Therapeutics Inc. is based in LOMA LINDA, CA.
| Revenue (Most Recent Fiscal Year) | $0.00M |
| Net Income (Most Recent Fiscal Year) | $-41.71M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 81.84 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -1339186.12% |
| Net Margin (Trailing 12 Months) | -999999.99% |
| Return on Equity (Trailing 12 Months) | -374.60% |
| Return on Assets (Trailing 12 Months) | -92.82% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.31 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.31 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.40 |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.61 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 0.90M |
| Free Float | 0.90M |
| Market Capitalization | $0.28M |
| Average Volume (Last 20 Days) | 2.60M |
| Beta (Past 60 Months) | 1.74 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.01% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |